Takeda Pharmaceutical (NYSE: TAK) counsel sells 30,868 ADSs to cover taxes

Rhea-AI Filing Summary

Takeda Pharmaceutical Co. Ltd. reported that its Global General Counsel, Natalie Anne Marie Furney, executed a sale of 30,868 American Depositary Shares on August 10, 2026. The sale, at a weighted average price of $17.10 per ADS, was a mandatory sale to cover taxes associated with the vesting of equity awards. Following this transaction, Furney directly holds 204,298 ADSs of Takeda.

Insider Trade Summary

Net Seller: 30,868 shares

Net Sell 1 txn

Insider Furney Natalie Anne Marie

Role Global General Counsel

Sold 30,868 shs ($528K)

Type	Security	Shares	Price	Value
Sale	American Depositary Shares F1, F2	30,868	$17.10	$528K

Holdings After Transaction: American Depositary Shares — 204,298 shares (Direct)

Footnotes (2)

1. F1. Represents a mandatory sale to cover taxes associated with the vesting of equity awards held by the Reporting Person.
2. F2. The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Key Figures

Shares sold: 30,868 ADSs Weighted average sale price: $17.10 per ADS Holdings after transaction: 204,298 ADSs +1 more

4 metrics

Shares sold 30,868 ADSs American Depositary Shares sold on August 10, 2026

Weighted average sale price $17.10 per ADS Price for the 30,868 ADSs sold to cover taxes

Holdings after transaction 204,298 ADSs Direct ownership of Natalie Anne Marie Furney following the sale

Net shares sold 30,868 ADSs Net sell direction across all reported transactions in this filing

Key Terms

American Depositary Shares, weighted average price, mandatory sale to cover taxes

3 terms

American Depositary Shares financial

"Represents a mandatory sale of American Depositary Shares to cover taxes"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

weighted average price financial

"The price reported in Column 4 is a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

mandatory sale to cover taxes financial

"Represents a mandatory sale to cover taxes associated with the vesting"

FAQ

What insider transaction did Takeda (TAK) disclose in this Form 4?

Takeda disclosed that Global General Counsel Natalie Anne Marie Furney sold 30,868 American Depositary Shares on August 10, 2026, in a mandatory sale to cover taxes on vested equity awards.

At what price were the 30,868 Takeda (TAK) ADSs sold by the executive?

The 30,868 ADSs were sold at a weighted average price of $17.10 per ADS. The filing notes this as a weighted average and offers to provide detailed breakdowns of individual sale prices upon request.

Why did Takeda’s (TAK) Global General Counsel sell 30,868 ADSs?

The sale of 30,868 ADSs was described as a mandatory sale to cover taxes arising from the vesting of equity awards, indicating it was undertaken to satisfy tax withholding obligations rather than discretionary portfolio rebalancing.

How many Takeda (TAK) ADSs does the reporting person hold after the sale?

After the August 10, 2026 transaction, Natalie Anne Marie Furney directly holds 204,298 American Depositary Shares of Takeda Pharmaceutical Co. Ltd., as reported in the post-transaction holdings column.

Was the Takeda (TAK) insider sale made under a Rule 10b5-1 trading plan?

The filing indicates the Rule 10b5-1 checkbox is not marked as affirmative, and the footnotes describe the transaction as a mandatory tax-cover sale, not as one executed under a pre-arranged Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/12/2026 - 09:24 PM Accepted by SEC EDGAR 08/12/2026 - 09:23 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Furney Natalie Anne Marie

(Last) (First) (Middle)

500 KENDALL STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TAKEDA PHARMACEUTICAL CO LTD [ TAK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Global General Counsel

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
American Depositary Shares	08/10/2026		S(1)		30,868	D	$17.1(2)	204,298	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a mandatory sale to cover taxes associated with the vesting of equity awards held by the Reporting Person.

2. The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

	/s/ Samuel Ntonme, by power of attorney, for Natalie A. Furney	08/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)